Pomerantz Law Firm Announces Class Action Suit Against GeneDx Holdings Corp: Investor Alert

Investor Alert: Class Action Lawsuit Filed Against GeneDx Holdings Corp.

On July 16, 2026, Pomerantz LLP, a prestigious law firm focused on investor rights, announced the initiation of a class action lawsuit against GeneDx Holdings Corp. (NASDAQ: WGS) amid allegations of securities fraud and other unlawful business practices. The firm urges investors who experienced losses to contact them for potential participation in the lawsuit.

Background on GeneDx Holdings

GeneDx, a company specializing in genomic testing, attracted attention earlier in 2025 when it announced plans to acquire Fabric Genomics, a firm renowned for its AI-driven genomic interpretation technologies. This acquisition was anticipated to enhance GeneDx's capabilities and market position. However, following the announcement of their first-quarter results in May 2026, the company's stock took a dramatic hit, raising concerns about its financial health and management practices.

Significant Financial Revelations

On May 4, 2026, GeneDx reported a disappointing financial outlook that saw its adjusted gross margin drop from 74% to 69%. Moreover, the firm revised its earnings projections downwards, estimating a range of $475-$490 million, compared to an earlier forecast of $540-$555 million. The significant $31.3 million impairment loss linked directly to the acquisition of Fabric Genomics has raised red flags about the company’s management strategy and financial oversight.

As a consequence of these troubling developments, GeneDx's share price plummeted by approximately 49.2%. Investors watched in dismay as the stock closed at $34.51 on May 5, down $33.42 from previous levels.

Call to Action for Affected Investors

Pomerantz LLP advises investors who purchased GeneDx securities during the Class Period to take action before the deadline of August 3, 2026. Those interested in leading the class action should reach out to Pomerantz by contacting Danielle Peyton at [email protected] or calling 646-581-9980. It’s crucial that affected investors include their mailing address, phone number, and details about the number of shares purchased in their correspondence to ensure they are included in any legal proceedings.

Expertise of Pomerantz Law Firm

Pomerantz LLP has a rich history of advocating for victims of corporate misdeeds and securities fraud. Since its founding by the late Abraham L. Pomerantz, the firm has established itself as a leader in class action litigation, recovering millions of dollars on behalf of aggrieved investors. With offices across major cities including New York, Chicago, and London, Pomerantz is committed to fighting systemic injustices in securities litigation.

The firm's efforts continue to reflect its dedication to holding corporations accountable for their actions. Prospective clients are encouraged to visit www.pomerantzlaw.com for more details and to view the complete complaint related to GeneDx's alleged malpractices.

For investors in GeneDx, the impending deadlines are critical. Taking swift action may secure their position in what could be a significant legal battle as the firm seeks justice for its clients. Investors who feel misled or have suffered losses should not hesitate to reach out and understand their rights in this evolving situation.